
    
      The study will evaluate the benefit of consolidation treatment with 90Y Ibritumomab tiuxetan
      (Zevalin®) or maintenance with rituximab (MabThera®) in terms of progression free survival,
      after induction with chemotherapy and rituximab in folicular lymphoma patients no treated
      previously.

      The other aims are, evaluate the global survival, event free survival, time until next
      treatment, response rate after consolidation or maintenance treatment, quality of life,
      security of two branches and relation cost-efectivity
    
  